King Pharmaceuticals KG Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.19M-0.1% | $10.21M-41.5% | $17.45M+214% | $5.56M+561% | $841K-31.1% | ||
| $11.74M-2.6% | $12.06M+11.8% | $10.78M+112% | $5.08M+344% | $1.14M+1.3% | ||
| -$6.95M— | —— | -$4.06M-106% | $70.43M+23,420% | -$302K— | ||
| $6K— | —— | $7K+133% | $3K-96.7% | $92K+207% | ||
| -$7.43M— | —— | -$5.05M-107% | $69.93M+17,848% | -$394K— | ||
| -72.9%— | —— | -29%-1,288pp | 1,258.8%+1,306pp | -46.8%— | ||
| -$0.96— | —— | -$0.65-104% | $15.05+10,850% | -$0.14— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is King Pharmaceuticals's revenue?
- King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
- Is King Pharmaceuticals profitable?
- King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
- What is King Pharmaceuticals's earnings per share?
- King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
- Where does King Pharmaceuticals's income statement data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
